Psilocybin for Smoking Cessation Shows Early Promise
A pilot randomized clinical trial suggests psilocybin with cognitive behavioral therapy may help more smokers quit than nicotine patch with the same counseling support.
In a small but important randomized clinical trial, smokers who received a single dose of psilocybin plus cognitive behavioral therapy were significantly more likely to remain abstinent at 6 months than those treated with nicotine patch plus the same therapy. The results suggest psilocybin may become a new option worth studying further for tobacco use disorder, though larger and more diverse trials are still needed.
Study Details
Smoking remains one of the leading causes of preventable death worldwide, and many people who want to quit still relapse within months despite currently available tools like nicotine replacement, bupropion, varenicline, and counseling. That treatment gap has pushed researchers to look at whether psychedelic-assisted therapy could help people break entrenched addictive patterns in a different way.
This new study, published in JAMA Network Open on March 10, 2026, tested whether psilocybin plus structured cognitive behavioral therapy could outperform an established smoking cessation treatment, the nicotine patch, when both were paired with the same counseling program.
The trial enrolled 82 psychiatrically healthy adult smokers at Johns Hopkins Bayview Medical Center in Baltimore. Participants had all tried to quit before and still wanted to stop smoking. The average age was 47.6 years, and participants smoked about 15.7 cigarettes per day on average at baseline.
Methodology
This was a pilot randomized clinical trial in which participants were assigned to one of two groups. One group received a single high dose of psilocybin at 30 mg/70 kg on the quit date, while the other began a standard 8 to 10 week nicotine patch regimen. Both groups also received the same 13-week manualized cognitive behavioral therapy program designed for smoking cessation.
Researchers followed participants for 6 months after the target quit date. Smoking abstinence was measured using not just self-report, but also biochemical verification, including exhaled carbon monoxide and urinary cotinine testing. The primary outcome was prolonged abstinence, meaning no smoking after an initial 2-week grace period. A secondary outcome looked at whether participants had avoided smoking during the previous 7 days at the 6-month mark.
Key Findings
40.5% of participants in the psilocybin group achieved biochemically verified prolonged abstinence at 6 months, compared with 10.0% in the nicotine patch group.
The psilocybin group had more than 6 times greater odds of prolonged abstinence at 6 months (OR 6.12).
52.4% of psilocybin-treated participants achieved 7-day point prevalence abstinence, compared with 25.0% in the nicotine patch group.
The psilocybin group had more than 3 times greater odds of 7-day abstinence at 6 months (OR 3.30).
Average cigarette use after the quit date was also lower in the psilocybin group, with model-predicted smoking about 53.7% lower than in the nicotine patch group.
No serious adverse events were attributed to either psilocybin or nicotine patch.
Psilocybin was associated with expected short-term side effects such as headache, temporary blood pressure elevation, nausea, and some visual disturbance, but these were generally managed within supervised sessions.
Implications for Practice
For patients, this study offers a cautious but meaningful signal that smoking cessation treatment may eventually expand beyond nicotine replacement and standard medications. A single supervised psychedelic session, paired with structured therapy, may help some smokers achieve longer-lasting behavior change than current routine approaches.
For clinicians, the most important takeaway is not that psilocybin is ready for routine practice today, but that it now has randomized trial data suggesting real potential in tobacco use disorder. The study used carefully selected participants, excluded people with important psychiatric risks, and provided substantial therapeutic support in a controlled medical setting. That means these results should not be generalized to unsupervised use or to all smokers.
There are also practical limitations. The trial was small, unblinded, highly motivated, and unusually familiar with psychedelics. The psilocybin group also had substantially more treatment-contact time than the nicotine patch group, which may have influenced outcomes. In addition, nicotine patch is not the most effective currently available comparator, since agents like varenicline or combination nicotine replacement may perform better in some settings.
Still, this study matters because tobacco dependence causes enormous long-term harm, and existing therapies often underperform in real-world settings. If larger confirmatory trials replicate these findings, psilocybin-assisted treatment could become an important future option for carefully screened patients, especially those who have repeatedly failed standard quit strategies.